

Indoco Remedies Limited

EARNINGS PRESENTATION

Q3/9M-FY26





7 Decades
of Presence in India



10 Manufacturing Facilities
6 FDF Plants
4 API Plants



EMPLOYEE
STRENGTH >6,000



Footprint
across 55+ countries
and expanding



Ranked 32nd
(IQVIA MAT Dec'25)
Ranked 21st
in Rx Report
(Dec'25) Source: IQVIA



R&D facility (300+ scientists)
Development of complex
ophthalmics & injectables
NDDS & New Platform
technologies Clinical Research
Organization Analytical Research
Services



7%
5 Year Revenue CAGR



Cyclopm, Febrex Plus, ATM,
Cital, Oxipod & Methycal are
some of the fastest growing
brands in the Domestic
formulation space




Net Debt to Equity: 0.68
Credit Rating:
Short Term Borrowings: 'A2+'
Long Term Borrowings: 'A(Negative)'

COMPANY OVERVIEW




- In 1945, our founder, Late Mr. Govind Ramnath Kare founded ‘**Indo-Continental Trading Company**’, the principal business of which was to import pharmaceutical formulations from Europe and distribute them in the Western India.
- In 1947 after India’s independence, one of the first endeavours of the Indian Government was to foster manufacturing of indigenous products. To encourage this, import of various items including several pharmaceutical products were banned. **Mr. Kare ventured into the manufacturing of pharmaceuticals and accordingly on 23rd August 1947, a week after India's independence, Indoco was founded with the intent to manufacture and sell pharmaceutical formulations.**
- The company is primarily engaged in the manufacturing and marketing of formulations (finished dosage forms) and Active Pharmaceutical Ingredients (APIs).
- We have **10 manufacturing facilities in India**, 6 for finished dosages and 4 for APIs, supported by a state-of-the-art R&D Centre and a Clinical Research Organization (CRO).
- The manufacturing facilities are **approved by various regulatory authorities** including USFDA, UK-MHRA and TGA-Australia.
- For the international markets, Indoco offers complete solutions, including product development, manufacture and supply of finished dosages, APIs and intermediates.
- Indoco has a large basket of products backed by ANDAs / eCTD dossiers and Drug Master Files (DMFs).


STANDALONE REVENUE (INR Mn) & EBITDA MARGINS (%)




BUSINESS SEGMENT (9M-FY26)



GEOGRAPHICAL FOOTPRINT



 Florida Pharmaceutical Products LLC
 (Acquired June 2023)

 Manufacturing – Formulations (6)

 Manufacturing – APIs (4)

 R&D Center (1)

 AnaCIPHER CRO

FINANCIAL HIGHLIGHTS



Q3/9M-FY26 HIGHLIGHTS



Standalone

Consolidated

Q3-FY26

INR 3,896 Mn Operating Income	INR 259 Mn Operating EBITDA	6.6 % Operating EBITDA Margins	INR 4,343 Mn Operating Income	INR 315 Mn Operating EBITDA	7.3 % Operating EBITDA Margins
INR (200) Mn Net Profit	(5.1) % PAT Margins	INR (2.17) /SHARE Diluted EPS (INR)	INR (295) Mn Net Profit	(6.8) % PAT Margins	INR (3.19) /SHARE Diluted EPS (INR)


9M-FY26

INR 12,045 Mn Operating Income	INR 941 Mn Operating EBITDA	7.8 % Operating EBITDA Margins	INR 13,370 Mn Operating Income	INR 921 Mn Operating EBITDA	6.9 % Operating EBITDA Margins
INR (330) Mn Net Profit	(2.7) % PAT Margins	INR (3.58) /SHARE Diluted EPS (INR)	INR (750) Mn Net Profit	(5.6) % PAT Margins	INR (8.13) /SHARE Diluted EPS (INR)


Q3-FY26 GEOGRAPHICAL BREAKUP




EXPORTS REVENUE BREAKUP




REGULATED MARKETS



DOMESTIC MARKET BREAKUP




EMERGING MARKETS



QUARTERLY KPI - FORMULATION BUSINESS




TOTAL REVENUE (INR Mn)




DOMESTIC REVENUE (INR Mn)

(IRL)




DOMESTIC REVENUE (INR Mn)

(IRL + WRPL)



INTERNATIONAL REVENUE (INR Mn)



FORMULATION BUSINESS–INDIA THERAPEUTIC & BRAND PERFORMANCE



INDIA THERAPEUTIC SEGMENT PERFORMANCE

PARTICULARS (INR MN)	Q3FY26	Q3FY25	Y-o-Y (%)	Q2FY26	Q-o-Q (%)
STOMATOLOGICALS*	568	511	11.1	526	8.1
RESPIRATORY	347	400	(13.2)	344	0.9
ANTI-INFECTIVES	324	332	(2.4)	430	(24.6)
GASTRO INTESTINAL	303	302	0.4	334	(9.3)
VITAMINS / MINERALS / NUTRIENTS	248	249	(0.5)	218	13.7
Urological	150	150	0.2	158	(4.7)
CARDIAC	115	111	3.1	99	16.4
OPHTHAL / OTOLOGICALS	113	124	(8.8)	120	(5.4)
DERMATOLOGY	99	97	1.9	115	(13.4)
PAIN / ANALGESICS	63	74	(13.8)	60	5.3

INDIA TOP BRANDS PERFORMANCE


PARTICULARS (INR MN)	Q3FY26	Q3FY25	Y-o-Y (%)	Q2FY26	Q-o-Q (%)
CYCLOPAM	245	266	(7.9)	269	(8.8)
FEBREX PLUS	156	175	(10.8)	186	(16.3)
CITAL	150	150	0.2	158	(4.7)
ATM	133	126	6.0	153	(13.1)
METHYCAL	131	157	(16.4)	94	40.1
OXIPOD	118	136	(13.1)	185	(36.1)
ATHEROCHEK	114	109	5.0	98	16.9
KARVOL	114	138	(17.8)	66	71.5
SM FIBRO	58	46	26.9	60	(2.5)
REXIDIN	82	86	(4.2)	86	(4.4)

*Stomatological Includes Sales of WRPL


QUARTERLY KPI – API/ALLIED SERVICE




DOMESTIC REVENUE (INR Mn)




INTERNATIONAL REVENUE (INR Mn)



TOTAL REVENUE (API) (INR Mn)



TOTAL REVENUE (Allied Services)
(INR Mn)



BUSINESS HIGHLIGHTS Q3/9M-FY26



- ❖ The 3rd quarter of this fiscal was marked by growth in International Formulation Business and API Business.
- ❖ Launch of Sensodent DSP and Sensodent DCP toothpastes were significant strategic step in our Domestic Formulation Business in the WRPL OTC segment.
- ❖ Un the Domestic formulations market, Indoco launched 1 (One) new product – Strawferri Tablets
- ❖ The Company ranked 21st in the IPM (Dec'25) as per IQVIA prescription ranking.
- ❖ The Company ranked 32nd in the IPM (MAT Dec'25) with market share of 0.52% as per IQVIA.
- ❖ Indoco received EIR from the USFDA for its API manufacturing plant at Patalganga.
- ❖ Indoco received the 'Most Preferred Workplace 2025-26' Award – by Marksmen Daily at Mumbai.

QUATERLY STANDALONE INCOME STATEMENT



PARTICULARS (INR Mn)	Q3-FY26	Q3-FY25	Y-o-Y (%)	Q2-FY26	Q-o-Q (%)
Operational Revenue	3,896	3,649	7	4,293	(9)
Operating Expenses	3,746	3,528	6	3,887	(4)
EBITDA	259	201	29	534	(51)
<i>EBITDA Margin (%)</i>	<i>6.6%</i>	<i>5.5%</i>	-	<i>12.4%</i>	-
Depreciation and Amortisation	274	248	11	276	(1)
Finance Costs	202	140	44	220	(8)
Other Income	72	43	68	65	10
PBT Before Exceptional Item	(144)	(144)	(1)	103	(240)
Exceptional Item	(60)	10	-	(5)	-
PBT	(205)	(134)	(53)	98	(310)
Tax Expense	(5)	(31)	86	(53)	91
PAT	(200)	(102)	(96)	151	(233)
<i>PAT Margin (%)</i>	<i>(5.1)%</i>	<i>(2.8)%</i>	-	<i>3.5%</i>	-
Other Comprehensive Income	(2)	(2)	(32)	6	(126)
Total Comprehensive Income	(202)	(105)	(93)	156	(229)
Diluted EPS (₹)	(2.17)	(1.11)	-	1.63	-

YTD STANDALONE STATEMENT



PARTICULARS (INR Mn)	YTD FY26	YTD FY25	Y-o-Y (%)
Operational Revenue	12,045	11,537	4
Operating Expenses	11,428	10,464	9
EBITDA	941	1,246	(24)
<i>EBITDA Margin (%)</i>	<i>7.8%</i>	<i>10.8%</i>	-
Depreciation and amortisation	802	734	9
Finance costs	658	407	62
Other Income	193	120	61
PBT Before Exceptional Item	(326)	225	(244)
Exceptional Item	(65)	10	-
PBT	(391)	235	(266)
Tax Expense	(61)	60	(201)
PAT	(330)	175	(289)
<i>PAT Margin (%)</i>	<i>(2.7)%</i>	<i>1.5%</i>	-
Other Comprehensive Income	8	(7)	224
Total comprehensive Income	(322)	168	(291)
Diluted EPS (₹)	(3.58)	1.90	-

QUARTERLY CONSOLIDATED INCOME STATEMENT



PARTICULARS (INR Mn)	Q3-FY26	Q3-FY25	Y-o-Y (%)	Q2-FY26	Q-o-Q (%)
Operational Revenue	4,343	4,025	8	4,718	(8)
Operating Expenses	4,139	3,985	4	4,416	(6)
EBITDA	315	120	162	431	(27)
<i>EBITDA Margin (%)</i>	<i>7.3%</i>	<i>3.0%</i>	-	<i>9.1%</i>	-
Depreciation and Amortisation	320	287	11	323	(1)
Finance Costs	256	161	59	246	4
Other Income	10	9	15	8	29
PBT Before Exceptional Item	(252)	(320)	21	(130)	(94)
Exceptional Item	(62)	10	-	(5)	-
PBT	(313)	(310)	(1)	(135)	(131)
Tax Expense	(19)	(26)	-	(43)	-
PAT	(295)	(284)	(4)	(92)	(220)
<i>PAT Margin (%)</i>	<i>(6.8)%</i>	<i>(7.1)%</i>	-	<i>(2.0)%</i>	-
Other Comprehensive Income	(13)	(1)	(869)	26	(149)
Total Comprehensive Income	(307)	(285)	(8)	(66)	(363)
Diluted EPS (₹)	(3.19)	(3.08)	-	(1.00)	-

YTD CONSOLIDATED STATEMENT



PARTICULARS (INR Mn)	9M-FY26	9M-FY25	Y-o-Y (%)
Operational Revenue	13,370	12,574	6
Operating Expenses	12,776	11,747	9
EBITDA	921	1,000	(8)
<i>EBITDA Margin (%)</i>	<i>6.9%</i>	<i>8.0%</i>	-
Depreciation and amortisation	940	851	10
Finance costs	763	483	58
Other Income	34	34	(2)
PBT Before Exceptional Item	(748)	(298)	151
Exceptional Item	(67)	10	-
PBT	(815)	(289)	182
Tax Expense	(65)	78	(184)
PAT	(750)	(366)	(105)
<i>PAT Margin (%)</i>	<i>(5.6)%</i>	<i>(2.9)%</i>	-
Other Comprehensive Income	12	(12)	198
Total comprehensive Income	(738)	(378)	(95)
Diluted EPS (₹)	(8.13)	(3.97)	-

HISTORICAL STANDALONE FINANCIAL PERFORMANCE




PARTICULARS (INR Mn)	FY23	FY24	FY25	9M-FY26
Operational Revenue	16,381	17,620	14,948	12,045
Operating Expenses	13,818	15,328	13,902	11,428
EBITDA	2,849	2,580	1,280	941
<i>EBITDA Margin (%)</i>	<i>17.4%</i>	<i>14.6%</i>	<i>8.6%</i>	<i>7.8%</i>
Depreciation and amortisation	706	880	983	802
Finance costs	250	368	566	658
Other Income	23	85	185	193
PBT Before Exceptional Item	1916	1417	(84)	(326)
Exceptional Item	0	115	10	(65)
PBT	1916	1532	(74)	(391)
Tax Expense	502	366	14	(61)
PAT	1414	1166	(87)	(330)
<i>PAT Margin (%)</i>	<i>8.6%</i>	<i>6.6%</i>	<i>(0.6)%</i>	<i>(2.7)%</i>
Other Comprehensive Income	14	0	(45)	8
Total Comprehensive Income	1428	1167	(132)	(322)
Diluted EPS (₹)	15.32	12.64	(0.95)	(3.58)

HISTORICAL CONSOLIDATED FINANCIAL PERFORMANCE



PARTICULARS (INR Mn)	FY23	FY24	FY25	9M-FY26
Operational Revenue	16,401	17,882	16,413	13,370
Operating Expenses	13,825	15,730	15,657	12,776
EBITDA	2,861	2,443	993	921
<i>EBITDA Margin (%)</i>	<i>17.4%</i>	<i>13.7%</i>	<i>6.0%</i>	<i>6.9%</i>
Depreciation and amortisation	706	919	1,138	940
Finance costs	250	380	662	763
Other Income	23	98	55	34
PBT Before Exceptional Item	1928	1243	(754)	(748)
Exceptional Item	0	115	10	(67)
PBT	1928	1358	(744)	(815)
Tax Expense	506	388	36	(65)
PAT	1423	970	(779)	(750)
<i>PAT Margin (%)</i>	<i>8.7%</i>	<i>5.4%</i>	<i>(4.7)%</i>	<i>(5.6)%</i>
Other Comprehensive Income	14	3	(41)	12
Total Comprehensive Income	1437	973	(821)	(738)
Diluted EPS (₹)	15.42	10.51	(8.45)	(8.13)


CAPITAL MARKET INFORMATION



MARKET DATA (INR) AS ON 31st December 2025

Face Value	2.0
CMP	234.8
52 Week H/L	348.1/190.0
Market Cap (INR Mn)	21,659.8
Shares O/S (Mn)	92.2
Avg. Volume ('000)	121.4

SHAREHOLDING PATTERN AS ON 31st December, 2025



DISCLAIMER



Indoco Remedies Limited Disclaimer:

No representation or warranty, express or implied, is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management of Indoco Remedies Limited, which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.

Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.

Valorem Advisors Disclaimer:

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.

For further details, please feel free to contact our Investor Relations Representatives:



Mr. Anuj Sonpal

Valorem Advisors

Tel: +91-22-4903-9500

Email: indoco@valoremadvisors.com

Investor kitlink: <https://www.valoremadvisors.com/INDOCO>

THANK YOU

